[go: up one dir, main page]

NO2961649T3 - - Google Patents

Info

Publication number
NO2961649T3
NO2961649T3 NO14709442A NO14709442A NO2961649T3 NO 2961649 T3 NO2961649 T3 NO 2961649T3 NO 14709442 A NO14709442 A NO 14709442A NO 14709442 A NO14709442 A NO 14709442A NO 2961649 T3 NO2961649 T3 NO 2961649T3
Authority
NO
Norway
Application number
NO14709442A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2961649T3 publication Critical patent/NO2961649T3/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO14709442A 2012-12-21 2014-02-28 NO2961649T3 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261740596P 2012-12-21 2012-12-21

Publications (1)

Publication Number Publication Date
NO2961649T3 true NO2961649T3 (fr) 2018-02-17

Family

ID=49917684

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14709442A NO2961649T3 (fr) 2012-12-21 2014-02-28

Country Status (46)

Country Link
US (3) US9040515B2 (fr)
EP (2) EP3339303B9 (fr)
JP (1) JP5909308B2 (fr)
KR (1) KR101712441B1 (fr)
CN (1) CN104870435B (fr)
AP (1) AP2015008574A0 (fr)
AR (1) AR094174A1 (fr)
AU (1) AU2013365908C1 (fr)
BR (1) BR112015014678B1 (fr)
CA (1) CA2893339C (fr)
CL (1) CL2015001733A1 (fr)
CR (2) CR20200273A (fr)
CU (1) CU24414B1 (fr)
CY (2) CY1119883T1 (fr)
DK (2) DK2935238T3 (fr)
DO (1) DOP2015000157A (fr)
EA (1) EA028317B1 (fr)
EC (1) ECSP15031579A (fr)
ES (2) ES2808987T3 (fr)
GE (1) GEP201706718B (fr)
GT (1) GT201500190A (fr)
HR (2) HRP20180060T1 (fr)
HU (2) HUE050009T2 (fr)
IL (1) IL239520B (fr)
LT (2) LT2935238T (fr)
MA (1) MA38175B1 (fr)
MD (1) MD4664C9 (fr)
ME (2) ME03793B (fr)
MX (2) MX2015008058A (fr)
MY (2) MY176307A (fr)
NO (1) NO2961649T3 (fr)
NZ (1) NZ708801A (fr)
PE (1) PE20151090A1 (fr)
PH (1) PH12015501367B1 (fr)
PL (2) PL3339303T3 (fr)
PT (2) PT3339303T (fr)
RS (2) RS56815B1 (fr)
SG (1) SG11201504076XA (fr)
SI (2) SI2935238T1 (fr)
TN (1) TN2015000281A1 (fr)
TR (1) TR201802791T4 (fr)
TW (1) TWI546293B (fr)
UA (1) UA111305C2 (fr)
UY (2) UY38712A (fr)
WO (1) WO2014097041A1 (fr)
ZA (1) ZA201504437B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2780013A4 (fr) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
US9085583B2 (en) 2012-02-10 2015-07-21 Constellation—Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
AR092742A1 (es) * 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
UA111305C2 (uk) * 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
JP6284547B2 (ja) 2012-12-21 2018-02-28 アリオス バイオファーマ インク. 置換ヌクレオシド、置換ヌクレオチドおよびそれらの類似体
EP2970305B1 (fr) 2013-03-15 2017-02-22 Constellation Pharmaceuticals, Inc. Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
WO2015023915A1 (fr) 2013-08-15 2015-02-19 Constellation Pharmaceuticals, Inc. Dérivés d'indole utilisés en tant que modulateurs d'enzymes de modification du méthyle, compositions et utilisations associées
MY185765A (en) 2014-06-17 2021-06-06 Pfizer Substituted dihydroisoquinolinone compounds
WO2015193768A1 (fr) * 2014-06-17 2015-12-23 Pfizer Inc. Lactames à fusion aryle à utiliser en tant que modulateurs ezh2
MA40848A (fr) * 2014-10-28 2021-05-05 Glaxosmithkline Ip No 2 Ltd Inhibiteurs d'ezh2 (enhancer of zeste homolog 2)
TW201636344A (zh) 2014-12-05 2016-10-16 美國禮來大藥廠 Ezh2抑制劑
EP3236962A2 (fr) 2014-12-23 2017-11-01 University of Copenhagen Traitement du cancer par inhibition de l'activité de l'ezh2
US10273221B2 (en) * 2015-03-27 2019-04-30 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives
TW201708210A (zh) * 2015-06-30 2017-03-01 葛蘭素史克智慧財產(第二)有限公司 Zeste同源物2增強子之抑制劑
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ezh2抑制劑
US10577350B2 (en) 2015-08-28 2020-03-03 Constellation Pharmaceuticals, Inc. Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
CN107428742B (zh) 2015-11-19 2020-05-08 江苏恒瑞医药股份有限公司 苯并呋喃类衍生物、其制备方法及其在医药上的应用
CA3023157A1 (fr) * 2016-05-05 2017-11-09 Glaxosmithkline Intellectual Property (No.2) Limited Activateur d'inhibiteurs de l'homologue 2 de zeste
WO2018075598A1 (fr) 2016-10-19 2018-04-26 Constellation Pharmaceuticals, Inc. Synthèse d'inhibiteurs d'ezh2
US20200262813A1 (en) * 2016-11-11 2020-08-20 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. 1,5,7-trisubstituted isoquinoline derivatives, preparation thereof, and use thereof in medicines
EP3824906A1 (fr) 2016-12-21 2021-05-26 Amgen Inc. Formulations d'anticorps anti-tnf alpha
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
RU2762893C2 (ru) 2017-05-18 2021-12-23 Цзянсу Хэнжуй Медсин Ко., Лтд. Применение ингибитора ezh2 в комбинации с ингибитором btk в получении лекарственного средства для лечения опухоли
AU2018269268B2 (en) 2017-05-18 2022-01-06 Jiangsu Hengrui Medicine Co., Ltd. Crystal of benzofuran derivative free base and preparation method
CN106977483A (zh) * 2017-06-02 2017-07-25 遵义医学院 一种二氟烷基取代的黄酮醇、异黄酮醇和香豆素类化合物的合成方法
CA3082287C (fr) 2017-11-14 2023-02-28 Pfizer Inc. Polytherapies faisant appel a un inhibiteur de ezh2
PT4043466T (pt) 2018-01-31 2024-10-14 Mirati Therapeutics Inc Inibidores de prc2
CN112533581B (zh) * 2018-06-07 2024-08-30 密歇根大学董事会 Prc1抑制剂及用其进行治疗的方法
WO2020011607A1 (fr) 2018-07-09 2020-01-16 Fondation Asile Des Aveugles Inhibition de sous-unités de prc2 permettant de traiter des troubles oculaires
EP3870173A4 (fr) * 2018-10-24 2022-06-22 Vanderbilt University Modulateurs et inhibiteurs de wdr5
CN111320582A (zh) * 2018-12-17 2020-06-23 江苏恩华药业股份有限公司 一种类酰胺类衍生物及其中间体的制备方法
KR102689665B1 (ko) * 2019-02-19 2024-07-31 한미약품 주식회사 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도
EP3959214A1 (fr) 2019-04-22 2022-03-02 Mirati Therapeutics, Inc. Dérivés de naphtyridine en tant qu'inhibiteurs de prc2
EP3980422A1 (fr) 2019-06-05 2022-04-13 Mirati Therapeutics, Inc. Dérivés d'imidazo [1,2-c]pyrimidine utilisés comme inhibiteurs de prc2 pour le traitement du cancer
KR102386403B1 (ko) * 2020-08-13 2022-04-15 한미약품 주식회사 신규한 디옥솔로이소퀴놀린온 유도체 화합물 및 이의 용도
US11535629B2 (en) * 2020-08-13 2022-12-27 Hanmi Pharmaceutical Co., Ltd. Dioxoloisoquinolinone derivatives and use thereof
WO2022179584A1 (fr) * 2021-02-26 2022-09-01 南京药石科技股份有限公司 Nouvel inhibiteur d'ezh2 et son utilisation
CN120476107A (zh) 2022-12-15 2025-08-12 先正达农作物保护股份公司 可用作杀有害生物剂的新型的二环-甲酰胺化合物
CN118978498B (zh) * 2024-10-22 2025-04-01 浙江雅辰药物科技股份有限公司 一种5-羟甲基四氢呋喃-3-醇的制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3846412A (en) 1971-03-18 1974-11-05 Lepetit Spa Dihydro-2-amino-isoquinolines and their derivatives
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (fr) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing-gum contenant des agents medicamenteux actifs
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
MX2008002207A (es) 2005-08-16 2008-03-27 Memory Pharm Corp Inhibidores de fosfodiesterasa 10.
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
US20110251216A1 (en) 2010-02-19 2011-10-13 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
WO2011140325A1 (fr) 2010-05-07 2011-11-10 Glaxosmithkline Llc Indazoles
US8637509B2 (en) 2010-05-07 2014-01-28 Glaxosmithkline Llc Azaindazoles
EP2566327B1 (fr) 2010-05-07 2017-03-29 Glaxosmithkline LLC Indoles
PL2614369T3 (pl) 2010-09-10 2016-08-31 Epizyme Inc Sposób określania przydatności inhibitorów ludzkiego ezh2 w leczeniu
JP2013537210A (ja) 2010-09-16 2013-09-30 ノバルティス アーゲー 17α−ヒドロキシラーゼ/C17,20−リアーゼ阻害剤
WO2012068589A2 (fr) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
JP2014511389A (ja) * 2011-02-28 2014-05-15 エピザイム インコーポレイテッド 置換6,5−縮合二環式ヘテロアリール化合物
TW201733984A (zh) * 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
BR112014007603A2 (pt) 2011-09-30 2017-06-13 Glaxosmithkline Llc métodos de tratamento do câncer
WO2013173441A2 (fr) 2012-05-16 2013-11-21 Glaxosmithkline Llc Inhibiteurs d'homologue d'activateur de zeste 2
WO2014049488A1 (fr) 2012-09-28 2014-04-03 Pfizer Inc. Composés de benzamide et hétérobenzamide
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
DK3067358T3 (da) 2012-12-21 2019-11-04 Gilead Sciences Inc Polycykliske carbamoylpyridon-forbindelser og deres farmaceutiske anvendelse
FR3000065A1 (fr) 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes
BR112015014752B1 (pt) 2012-12-21 2022-07-05 Plexxikon, Inc Compostos e seus uso para modulação de cinase
PT2934568T (pt) 2012-12-21 2018-01-04 Sanofi Sa Agonistas duplos de glp1/gip ou trigonais de glp1/gip/glucagina
EP3498701B1 (fr) 2012-12-21 2023-02-22 Epizyme Inc Inhibiteurs de prmt5 et utilisations associées
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
CN104870466B (zh) 2012-12-21 2018-05-18 霍夫曼-拉罗奇有限公司 作为催产素激动剂的肽
FR3000059A1 (fr) 2012-12-21 2014-06-27 Saint Gobain Placo Composition pour plaques de platre et produits obtenus
JP6284547B2 (ja) 2012-12-21 2018-02-28 アリオス バイオファーマ インク. 置換ヌクレオシド、置換ヌクレオチドおよびそれらの類似体
MY185765A (en) 2014-06-17 2021-06-06 Pfizer Substituted dihydroisoquinolinone compounds

Also Published As

Publication number Publication date
SI2935238T1 (en) 2018-04-30
HRP20201194T1 (hr) 2020-11-13
KR101712441B1 (ko) 2017-03-07
EA028317B1 (ru) 2017-11-30
CY1119883T1 (el) 2018-06-27
DK3339303T3 (da) 2020-08-10
AP2015008574A0 (en) 2015-07-31
HRP20201194T2 (hr) 2021-09-17
ES2808987T9 (es) 2021-11-29
US20140179667A1 (en) 2014-06-26
EP3339303B9 (fr) 2021-07-21
SI3339303T1 (sl) 2020-09-30
JP2016507497A (ja) 2016-03-10
MD4664B1 (ro) 2019-12-31
US10246433B2 (en) 2019-04-02
PH12015501367B1 (en) 2018-08-03
MD20150052A2 (ro) 2015-12-31
CR20200273A (es) 2020-09-23
IL239520A0 (en) 2015-08-31
TW201446753A (zh) 2014-12-16
EP2935238A1 (fr) 2015-10-28
TR201802791T4 (tr) 2018-03-21
RS60582B1 (sr) 2020-08-31
US20170233368A1 (en) 2017-08-17
LT2935238T (lt) 2018-02-26
IL239520B (en) 2018-05-31
ME02980B (fr) 2018-10-20
EA201590879A1 (ru) 2015-12-30
MY192259A (en) 2022-08-12
UY35225A (es) 2014-07-31
BR112015014678B1 (pt) 2021-12-07
DOP2015000157A (es) 2015-11-30
PT2935238T (pt) 2018-02-09
SG11201504076XA (en) 2015-06-29
EP3339303A1 (fr) 2018-06-27
LT3339303T (lt) 2020-09-10
MD4664C9 (ro) 2020-07-31
ME03793B (fr) 2021-04-20
AU2013365908B2 (en) 2017-07-20
CR20150279A (es) 2015-09-03
ECSP15031579A (es) 2017-08-31
TN2015000281A1 (fr) 2016-10-03
JP5909308B2 (ja) 2016-04-26
UY38712A (es) 2020-06-30
AR094174A1 (es) 2015-07-15
PE20151090A1 (es) 2015-08-07
AU2013365908A1 (en) 2015-06-11
HUE038238T2 (hu) 2018-10-29
MA38175B1 (fr) 2018-11-30
PH12015501367A1 (en) 2015-09-02
CY1123237T1 (el) 2021-10-29
CN104870435B (zh) 2016-12-07
CL2015001733A1 (es) 2015-10-23
EP2935238B1 (fr) 2017-12-27
CU24414B1 (es) 2019-05-03
MX2020002924A (es) 2020-07-22
PL3339303T3 (pl) 2021-01-25
HK1208866A1 (en) 2016-03-18
MA38175A1 (fr) 2018-08-31
GEP201706718B (en) 2017-08-10
NZ708801A (en) 2018-08-31
PL2935238T3 (pl) 2018-05-30
CU20150062A7 (es) 2015-11-27
ES2808987T3 (es) 2021-03-02
TWI546293B (zh) 2016-08-21
AU2013365908C1 (en) 2018-01-25
HUE050009T2 (hu) 2020-11-30
MY176307A (en) 2020-07-28
HRP20180060T1 (hr) 2018-02-23
PT3339303T (pt) 2020-07-30
GT201500190A (es) 2016-01-21
CA2893339A1 (fr) 2014-06-26
EP3339303B1 (fr) 2020-06-24
RS60582B9 (sr) 2021-09-30
ES2658974T3 (es) 2018-03-13
CA2893339C (fr) 2017-06-13
RS56815B1 (sr) 2018-04-30
US20150175572A1 (en) 2015-06-25
CN104870435A (zh) 2015-08-26
DK2935238T3 (en) 2018-01-22
KR20150100823A (ko) 2015-09-02
UA111305C2 (uk) 2016-04-11
US9040515B2 (en) 2015-05-26
BR112015014678A2 (pt) 2017-07-11
ZA201504437B (en) 2016-07-27
MX2015008058A (es) 2015-10-30
WO2014097041A1 (fr) 2014-06-26

Similar Documents

Publication Publication Date Title
BR112014017635A2 (fr)
BR112014017614A2 (fr)
BR112014017625A2 (fr)
BR112014017659A2 (fr)
BR112014017592A2 (fr)
BR112014017646A2 (fr)
BR112014017607A2 (fr)
BR112014017638A2 (fr)
AR092201A1 (fr)
BR112013027865A2 (fr)
BR112014017609A2 (fr)
BR112014017634A2 (fr)
BR112014017644A2 (fr)
BR112014017588A2 (fr)
BR112014017618A2 (fr)
BR112014017647A2 (fr)
BR112014013184A8 (fr)
BR112014017623A2 (fr)
BR112014017652A2 (fr)
BR112014017630A2 (fr)
BR112014017627A2 (fr)
BR112014017621A2 (fr)
BR112014017631A2 (fr)
BR112014017641A2 (fr)
BR112014017622A2 (fr)